This wiki has undergone a migration to Confluence found Here
Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"
Jump to navigation
Jump to search
Kirt Schaper (talk | contribs) (Created page with " {{subst::Template:FHIR Resource Proposal}}") |
Kirt Schaper (talk | contribs) (initial edit) |
||
| Line 13: | Line 13: | ||
| − | = | + | =BiologicallyDerivedProduct= |
<!-- Resource names should meet the following characteristics: | <!-- Resource names should meet the following characteristics: | ||
| Line 30: | Line 30: | ||
<!-- The name of the committee that is proposed to have responsibility for developing and maintaining the resources. --> | <!-- The name of the committee that is proposed to have responsibility for developing and maintaining the resources. --> | ||
| − | [[ | + | [[Patient Care]] |
==Committee Approval Date:== | ==Committee Approval Date:== | ||
<i>Please enter the date that the committee approved this Resource proposal</i> | <i>Please enter the date that the committee approved this Resource proposal</i> | ||
| Line 37: | Line 37: | ||
<!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | <!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the resource (optional) --> | ||
| − | * | + | * Orders and Observations |
| − | |||
| − | |||
==FHIR Resource Development Project Insight ID== | ==FHIR Resource Development Project Insight ID== | ||
| Line 57: | Line 55: | ||
As a rule, resources should encompass all of these aspects. | As a rule, resources should encompass all of these aspects. | ||
--> | --> | ||
| + | Substances taken from one biological entity (person, animal, etc) or modifications of such substances, intended to be injected, transplanted or grafted to another (possibly the same) biological entity. This includes but is not limited to: | ||
| + | * blood (whole, extracted cells, plasma, etc) | ||
| + | * hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction) | ||
| + | * organs | ||
| + | * tissues (porcine valves, skin, bovine cardiac tissue, etc.) | ||
| + | * manipulated cells (e.g. CAR T-cells) | ||
==RIM scope== | ==RIM scope== | ||
Revision as of 21:33, 9 September 2017
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Example Scenarios
- 1.11 Resource Relationships
- 1.12 Timelines
- 1.13 gForge Users
- 1.14 When Resource Proposal Is Complete
- 1.15 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal
Contributing or Reviewing Work Groups
- Orders and Observations
FHIR Resource Development Project Insight ID
Scope of coverage
Substances taken from one biological entity (person, animal, etc) or modifications of such substances, intended to be injected, transplanted or grafted to another (possibly the same) biological entity. This includes but is not limited to:
- blood (whole, extracted cells, plasma, etc)
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
RIM scope
Resource appropriateness
Expected implementations
Content sources
Example Scenarios
Resource Relationships
Timelines
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
